Keith Stewart, MB, CHB, UHN and Princess Margaret Hospital

Future of BCMA-Targeted Therapies in Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Bispecific Antibodies for Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Differentiating among CAR T Products for Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Development of CAR T Cells in Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Using Antibody-Drug Conjugates in Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

BCMA-Targeted Therapies in Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

BELLINI Trial; Venetoclax-Vd in Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

BOSTON Study; SVd in Relapsed/Refractory Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Lenalidomide-Refractory Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Daratumumab With Carfilzomib in Frontline Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Management of Relapsed/Refractory Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Maintenance Therapy Approaches in Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

MRD Monitoring in Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

The Role of Transplant in Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Treating Transplant-Eligible and -Ineligible MM

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Transplant-Ineligible Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Tolerability of Triplet Therapy in Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Frontline Triplet Therapies in Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Dr. Stewart on the Role of Transplant in Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital

April 13th 2018

Keith Stewart, MB, CHB, professor of medicine, consultant, Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, discusses the role of transplant in patients with multiple myeloma.

Articles by Keith Stewart, MB, CHB, UHN and Princess Margaret Hospital

Future of BCMA-Targeted Therapies in Multiple Myeloma

Bispecific Antibodies for Multiple Myeloma

Differentiating among CAR T Products for Multiple Myeloma

Development of CAR T Cells in Multiple Myeloma

Using Antibody-Drug Conjugates in Multiple Myeloma

BCMA-Targeted Therapies in Multiple Myeloma

BELLINI Trial; Venetoclax-Vd in Multiple Myeloma

BOSTON Study; SVd in Relapsed/Refractory Multiple Myeloma

Lenalidomide-Refractory Multiple Myeloma

Daratumumab With Carfilzomib in Frontline Multiple Myeloma

Management of Relapsed/Refractory Multiple Myeloma

Maintenance Therapy Approaches in Multiple Myeloma

MRD Monitoring in Multiple Myeloma

The Role of Transplant in Multiple Myeloma

Treating Transplant-Eligible and -Ineligible MM

Transplant-Ineligible Multiple Myeloma

Tolerability of Triplet Therapy in Multiple Myeloma

Frontline Triplet Therapies in Multiple Myeloma

Dr. Stewart on the Role of Transplant in Multiple Myeloma

Latest Updated Articles

Trending on OncLive

FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care

Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma

Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies

TRX103 Tr1 Cell Therapy Shows Manageable Safety and Dose-Dependent Kinetics After HLA-Mismatched HCT in Hematologic Malignancies

Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma